We believe that the combination of the newly identified drugs targeting the RAD54-BLM interaction with conventional chemotherapeutic regimens might represent an attractive therapeutic option and, thereby, serve as adjunct therapy for patients with colon cancer. This evidence concerns the gene ATRX and colonic neoplasm.